1-year results of combined half-dose photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy

被引：0
|
作者：
Ian Y. Wong
Xuan Shi
Rita Gangwani
Paul Zhao
Lawrence P. Iu
Qing Li
Alex Ng
Xiaoxin Li
机构：
[1] The University of Hong Kong,Department of Ophthalmology, LKS Faculty of Medicine
[2] Peking University People’s Hospital,Department of Ophthalmology
[3] National University Hospital,Department of Ophthalmology
来源：
BMC Ophthalmology | / 15卷
关键词：
Age related macular degeneration; Half-dose; Half-fluence; Photodynamic therapy; Polypoidal choroidal vasculopathy; Ranibizumab; Verteporfin;
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
相关论文
共 50 条
  • [21] Retreatment of polypoidal choroidal vasculopathy after photodynamic therapy combined with intravitreal ranibizumab
    Kikushima, Wataru
    Sakurada, Yoichi
    Sugiyama, Atsushi
    Tanabe, Naohiko
    Yoneyama, Seigo
    Iijima, Hiroyuki
    JAPANESE JOURNAL OF OPHTHALMOLOGY, 2017, 61 (01) : 61 - 66
  • [22] Retreatment of polypoidal choroidal vasculopathy after photodynamic therapy combined with intravitreal ranibizumab
    Wataru Kikushima
    Yoichi Sakurada
    Atsushi Sugiyama
    Naohiko Tanabe
    Seigo Yoneyama
    Hiroyuki Iijima
    Japanese Journal of Ophthalmology, 2017, 61 : 61 - 66
  • [23] One-year Results of Intravitreal Ranibizumab Combined with Reduced-Fluence Photodynamic Therapy for Polypoidal Choroidal Vasculopathy
    Yamanouchi, Daisuke
    Sakurai, Madoka
    Baba, Takayuki
    Kitahashi, Masayasu
    Yokouchi, Hirotaka
    Kubota-Taniai, Mariko
    Yamamoto, Shuichi
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [24] Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy: a 2-year result and systematic review
    Zhao, Meng
    Zhou, Hai-Ying
    Xu, Jun
    Zhang, Feng
    Wei, Wen-Bin
    Liu, Ning-Pu
    INTERNATIONAL JOURNAL OF OPHTHALMOLOGY, 2017, 10 (03) : 413 - 422
  • [25] Combined photodynamic therapy and ranibizumab for polypoidal choroidal vasculopathy:a 2-year result and systematic review
    Meng Zhao
    Hai-Ying Zhou
    Jun Xu
    Feng Zhang
    Wen-Bin Wei
    Ning-Pu Liu
    International Journal of Ophthalmology, 2017, (03) : 413 - 422
  • [26] Two-year follow-up of ranibizumab combined with photodynamic therapy for polypoidal choroidal vasculopathy
    Nemoto, Rei
    Miura, Masahiro
    Iwasaki, Takuya
    Goto, Hiroshi
    CLINICAL OPHTHALMOLOGY, 2012, 6 : 1633 - 1638
  • [27] One-year results of intravitreal ranibizumab combined with reduced-fluence photodynamic therapy for polypoidal choroidal vasculopathy.
    Sakurai, Madoka
    Baba, Takayuki
    Kitahashi, Masayasu
    Yokouchi, Hirotaka
    Kubota-Taniai, Mariko
    Bikbova, Guzel
    Oshitari, Toshiyuki
    Yamamoto, Shuichi
    CLINICAL OPHTHALMOLOGY, 2014, 8 : 235 - 241
  • [28] Prognostic factors for combined ranibizumab and prompt verteporfin photodynamic therapy for polypoidal choroidal vasculopathy
    Hsia, Yun
    Chan, Li-Wei
    Yang, Chang-Hao
    Yang, Chung-May
    Hsieh, Yi-Ting
    PHOTODIAGNOSIS AND PHOTODYNAMIC THERAPY, 2019, 27 : 227 - 233
  • [29] CORRELATION BETWEEN CHANGES IN SUBFOVEAL CHOROIDAL THICKNESS AND 1-YEAR OUTCOMES OF RANIBIZUMAB THERAPY FOR POLYPOIDAL CHOROIDAL VASCULOPATHY
    Hikichi, Taiichi
    Kitamei, Hirokuni
    Shioya, Shoko
    Higuchi, Makoto
    Matsushita, Takuro
    Kosaka, Shoko
    Matsushita, Reiko
    Takami, Kimitaka
    Ohtsuka, Hideo
    INVESTIGATIVE OPHTHALMOLOGY & VISUAL SCIENCE, 2013, 54 (15)
  • [30] Five-year outcomes of photodynamic therapy combined with intravitreal injection of ranibizumab or aflibercept for polypoidal choroidal vasculopathy
    Wataru, Kikushima
    Sugiyama, Atsushi
    Yoneyama, Seigo
    Matsubara, Mio
    Fukuda, Yoshiko
    Parikh, Ravi
    Sakurada, Yoichi
    PLOS ONE, 2020, 15 (02):
12345